Table 6.
Univariate and multivariate analyses of the prognostic factors of overall survival (OS) in the PSM cohort.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P- value | |
| Age, years (<55/≥55) | 1.093 | 0.893-1.399 | 0.387 | |||
| Gender (Male/Female) | 1.171 | 0.952-1.440 | 0.134 | |||
| ECOG PS score (0/1-2) | 1.295 | 1.056-1.588 | 0.013 | 1.268 | 1.032-1.557 | 0.024 |
| Primary tumor site ( Left /Right ) | 1.531 | 1.207-1.897 | <0.001 | 1.491 | 1.187-1.873 | 0.001 |
| Tumor grade (G1-2/G3) | 1.445 | 1.141-1.831 | 0.003 | 1.448 | 1.141-1.836 | 0.002 |
| Number of metastatic organs (1/≥2) | 0.878 | 0.716-1.078 | 0.216 | |||
| Primary/Metastatic tumor resection (Yes/No) | 1.347 | 1.100-1.650 | 0.004 | 1.309 | 1.066-1.606 | 0.010 |
| Chemotherapy (Chemo/combination) | 0.957 | 0.767-1.195 | 0.700 | |||
| CEA (ng/ml) (<5/≥5) | 1.751 | 1.410-2.173 | <0.001 | 1.573 | 1.249-1.981 | <0.001 |
| CA19-9 (ng/ml) (<35/≥35) | 1.721 | 1.401-2.115 | <0.001 | 1.469 | 1.181-1.828 | 0.001 |
| Cholesterols (mmol/L) (≤6.47/>6.47) | 1.109 | 0.779-1.578 | 0.565 | |||
| Triglycerides (mmol/L) (≤1.70/>1.70) | 0.814 | 0.634-1.044 | 0.105 | |||
| HDL-C (mmol/L) (≥0.78/<0.78) | 1.413 | 1.034-1.932 | 0.030 | |||
| LDL-C (mmol/L) (≤3.40/>3.40) | 1.308 | 1.062-1.612 | 0.012 | |||
| ApoA-I (ng/L) (≥1.05/<1.05) | 1.386 | 0.760-2.527 | 0.287 | |||
| ApoB (ng/L) (≤1.15/>1.15) | 1.250 | 0.993-1.574 | 0.057 | |||
| LDL-C/HDL-C (<2.55/≥2.55) | 1.299 | 1.059-1.594 | 0.012 | |||
| ApoB/ApoA-I (<0.69/≥0.69) | 1.485 | 1.196-1.843 | < 0.001 | 1.599 | 1.287-1.988 | <0.001 |
* PSM cohort: propensity score matching cohort; ECOG PS score: Eastern Cooperative Oncology Group performance status score; CEA: serum carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: apolipoprotein A-I; ApoB: apolipoprotein B; LDL-C/HDL-C: LDL-C to HDL-C ratio; ApoB/ApoA-I: ApoB to ApoA-I ratio.